New England Surgical Society (NESS)
Search NESS
  Annual Meeting
  Annual Resident and Fellow Research Day
      Member Directory
      Members Only
  Scholars Foundation
  Job Board
  Journal of the American College of Surgeons
      Past Presidential Addresses
  Contact NESS


Twenty-year Experience with Liver Transplantation for Hepatocellular Carcinoma

Eddie R Island, James Pomposelli, Elizabeth A. Pomfret, Fredric D. Gordon, W. David Lewis, Roger L. Jenkins
Lahey Clinic, Burlington, MA

Liver transplantation (LT) has become the optimal treatment for stage I & II hepatocellular carcinoma (HCC). Herein we present our results of a 20 year experience, including long term followup, of LT for the treatment of HCC.
Outcomes Study
Tertiary Care Center.
Patients: Retrospective review of prospectively collected data was preformed on a cohort of 92 patients who underwent LT for HCC between1983 and 2003.
Main Outcome Measures:
Patient demographics, tumor stage in the explant liver, patient survival and tumor recurrence data were analyzed.
The average follow up was 1052 (0-6491) days. The average tumor size was 3.6 cm, with 40% multi focal and 60% unifocal tumors. Stage I patients were 26%, while 42% were stage II, 24% were stage III, and 8% were stage IV. Overall 5-year survival was 50%, 10-year survival was 32 % and 15-year survival was 27%. Improvements in staging over the last five years has reduced the number of Stage III & IV patients from 39% to 19%, and has increased the 5 year survival to 69%. Tumor recurrence was relatively rare (13%), however recurrence resulted in a poor prognosis (75% mortality, p=0.02). The average time to recurrence was 460 days (179-1195).
LT for HCC results in excellent long-term survival for Stage I &II HCC with relatively few patients dying from tumor recurrence. Improvements in preoperative staging have resulted in improved 5-year survival. Further refinements in pretransplant staging may increase the effectiveness of LT for HCC.

Back to Final Program


Copyright © 2020 New England Surgical Society. All Rights Reserved.
Read Privacy Policy.